Maurer, C
Langerbeins, P
Bahlo, J
Cramer, P
Fink, A M
Pflug, N
Engelke, A
von Tresckow, J
Kovacs, G
Stilgenbauer, S
Wendtner, C-M
Müller, L
Ritgen, M
Seiler, T
Fischer, K
Hallek, M
Eichhorst, B
,
Article History
Received: 23 December 2015
Revised: 23 March 2016
Accepted: 5 April 2016
First Online: 2 May 2016
Competing interests
: BE received honoraria from Roche and Mudipharma for educational presentations. BE declared advisory board membership for Roche and Mundipharma. BE received research grants form Roche and Mundipharma and travel grants from Mundipharma. CM received travel grants from Mundipharma. PL received travel grants from Janssen, Roche and Mundipharma. PC received travel grants from Roche, Mundipharma and Janssen. NP received honoraria from Novartis and travel grants from JazzPharma and Celgene. AE received travel grants from Roche. JvT received travel grants from Celgene and Roche, research funding by Roche and Janssen and honoraria by Janssen. GK received travel grants from Celgene. SS received honoraria from Roche for educational presentations. SS declared advisory board membership of Roche. SS received research grants from Roche. SS received travel grants from Roche. C-MW received honoraria from Roche and Mundipharma. C-MW declared advisory board membership of Roche and Mundipharma. C-MW received research grants from Roche and Mundipharma and travel grants from Roche and Mundipharma. LM declared advisory board membership of Roche. MR received honoraria from Roche for educational presentations. MR received travel grants from Roche. KF received travel grants from Roche. MH declared advisory board membership of Roche and Celgene. MH declared participation in speakers’ bureau from Roche, Celgene, Mundipharma and Janssen. MH received research grants from Roche, Celgene and Janssen. JB, AMF and TS declare no conflict of interest.